Patent US4018919A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4018919A Expired / Lapsed US ⏱️ 0.0 years remaining

Sequential contraceptive method using two types of progestational agents

Assignee: Eli Lilly and Co
•
Filing: 1975-07-16
•
Granted: 1977-04-19
•
Expires: 1995-07-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Sequential administration of specified progestational agents to a female mammal during the follicular and luteal phases of the sexual cycle provides a novel and effective method of contraception.

Inventors

  • 👤 Larry J. Black

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 03:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 48 words
A method of contraception for female mammals which comprises the administration to a female mammal of a Type B progestin during the follicular phase of the sexual cycle and a Type A progestin during the luteal phase of the sexual cycle, at dose levels sufficient to prevent conception.
Claim 2
Independent Claim 48 words
A method of contraception for female mammals which comprises the administration to a female mammal of a Type B progestin during the follicular phase of the sexual cycle and a Type A progestin during the luteal phase of the sexual cycle, at dose levels sufficient to prevent conception.
Claim 3
Dependent Claim 22 words
The method according to claim 1 in which the Type B progestin is chlormadinone acetate and the Type A progestin is norethindrone.
Claim 4
Dependent Claim 63 words
The method according to claim 1 in which the Type B progestin is administered at a rate equivalent to administration of 0.166 to 8.33 mcg. of chlormadinone per kg. of female body weight per day and the Type A progestin is administered at a rate equivalent to administration of 0.0017 to 0.0833 mg. of norethindrone per kg. of female body weight per day.
Claim 5
Independent Claim 58 words
A method of contraception for human females which comprises oral administration to a human female of a Type B progestin during the follicular phase of the menstrual cycle -- from about day 6 through day 16 -- and a Type A progestin during the luteal phase of the menstrual cycle -- from about day 17 through day 28.
Claim 6
Independent Claim 58 words
A method of contraception for human females which comprises oral administration to a human female of a Type B progestin during the follicular phase of the menstrual cycle -- from about day 6 through day 16 -- and a Type A progestin during the luteal phase of the menstrual cycle -- from about day 17 through day 28.
Claim 7
Dependent Claim 21 words
The method according to claim 4 in which chlormadinone is the Type B progestin and norethindrone is the Type A progestin.
Claim 8
Dependent Claim 50 words
The method according to claim 4 in which the daily dosage level of the Type B progestin in the follicular phase is equivalent to of 10-50 mcg. of chlormadinone and the daily dosage level of the Type A progestin in the luteal phase is equivalent to 0.1-5 mg. of norethindrone.
Claim 9
Dependent Claim 51 words
A contraceptive process which comprises oral administration to a human female of from 10-500 mcg. of chlormadinone daily during the follicular phase of the menstrual cycle -- day 6 day 16 -- followed by administration of 0.1 - 5 mg. of norethindrone daily during the luteal phase of the menstrual cycle.
Claim 10
Dependent Claim 51 words
A contraceptive process which comprises oral administration to a human female of from 10-500 mcg. of chlormadinone daily during the follicular phase of the menstrual cycle -- day 6 day 16 -- followed by administration of 0.1 - 5 mg. of norethindrone daily during the luteal phase of the menstrual cycle.

References Cited (Backward Citations)

US3366651A Cited
US3758687A Cited
US3409721A Cited
US3499013A Cited
US3795734A Cited
US3711521A Cited
US3892842A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-04-18 1980-10-18 1981-04-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-04-18 1984-10-18 1985-04-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-04-18 1988-10-18 1989-04-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag